COMMUNIQUÉS West-GlobeNewswire

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
13/12/2024
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the [...]
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
13/12/2024
BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and [...]
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
13/12/2024
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the [...]
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
13/12/2024
Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
The Ensign Group, Inc. Increases Quarterly Dividend to $0.0625 Per Share
13/12/2024
SAN JUAN CAPISTRANO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
‘A Tragedy in the Making’: Approval of Canada’s Proposed $32.5 Billion Big Tobacco Settlement Risks Leaving Millions Living with Lung Disease Behind, Warns National Lung Health Alliance (NLHA)
13/12/2024
Leading patient advocacy network urges provinces to use settlement pay-outs solely to combat lung disease following historic creditors vote on December 12 TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The National Lung [...]
La formulation sous-cutanée de DARZALEX® (daratumumab) démontre une réduction de 51 pour cent du risque de progression vers un myélome multiple actif chez des patients atteints d’un myélome multiple indolent à haut risque
13/12/2024
Le premier traitement sous-cutané anti-CD38 à démontrer un potentiel de prévention des lésions au niveau des organes cibles et de prolongation de la survie sans progression et de la survie globale, d’après les résultats [...]
ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference
13/12/2024
Garching / Munich, Germany, December 13, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer, Dr. Andrew Cavey and Chief [...]
Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle
13/12/2024
London, UK – 13 th December 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage speciality pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle [...]
Candel Therapeutics Announces $80 Million Proposed Public Offering
12/12/2024
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help [...]
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
12/12/2024
No impact at this time on the listing of the Company’s Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” [...]
NeuroPace to Host Investor Day on January 28th in New York City
12/12/2024
MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will [...]
Results of Scheme Meeting
12/12/2024
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“ Bionomics ” or the “ Company ”) is pleased to provide the following update on the status of its proposed re [...]
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing
12/12/2024
Business combination closed November 13, 2024 Raised $10 million of gross proceeds in connection with the business combination Agreements are in place with Yorkville for up to a $50 million standby equity purchase [...]
Beacon Biosignals Reports Novel Sleep EEG Results from Multiple Industry Collaborations at the American Epilepsy Society Annual Meeting
12/12/2024
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, the global leader in at-home EEG and AI-powered brain health analytics, presented two scientific posters at the American Epilepsy Society (AES) Annual Meeting [...]
Boundless Bio Announces Pipeline and Leadership Updates
12/12/2024
Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027, through [...]
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
12/12/2024
PDUFA goal date is July 27, 2025 COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its [...]
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
12/12/2024
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from [...]
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
12/12/2024
Focus on in vivo CRISPR-edited medicines based on Editas researchers’ recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF [...]

Pages